WO2006077152A3 - Hla fusion molecules and uses thereof - Google Patents

Hla fusion molecules and uses thereof Download PDF

Info

Publication number
WO2006077152A3
WO2006077152A3 PCT/EP2006/000560 EP2006000560W WO2006077152A3 WO 2006077152 A3 WO2006077152 A3 WO 2006077152A3 EP 2006000560 W EP2006000560 W EP 2006000560W WO 2006077152 A3 WO2006077152 A3 WO 2006077152A3
Authority
WO
WIPO (PCT)
Prior art keywords
domain
diseases
fusion molecules
hla
fusion molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2006/000560
Other languages
French (fr)
Other versions
WO2006077152A2 (en
Inventor
Nalan Utku
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to EP06706364A priority Critical patent/EP1919949A2/en
Priority to CA002595462A priority patent/CA2595462A1/en
Publication of WO2006077152A2 publication Critical patent/WO2006077152A2/en
Publication of WO2006077152A3 publication Critical patent/WO2006077152A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention provides a fusion molecule comprising a first domain and a second domain, wherein said first domain comprises the HLA-DR alpha 2 domain or a fragment thereof. Said fusion molecule is capable of modulating the T-cell mediated immune response. Furthermore, pharmaceutical compositions comprising said fusion molecules for the treatment of various diseases such as graft versus host disease, autoimmune diseases, allergic diseases, infectious diseases and tumors in a subject are described.
PCT/EP2006/000560 2005-01-21 2006-01-23 Hla fusion molecules and uses thereof Ceased WO2006077152A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP06706364A EP1919949A2 (en) 2005-01-21 2006-01-23 Hla fusion molecules and uses thereof
CA002595462A CA2595462A1 (en) 2005-01-21 2006-01-23 Hla fusion molecules and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64599205P 2005-01-21 2005-01-21
US60/645,992 2005-01-21

Publications (2)

Publication Number Publication Date
WO2006077152A2 WO2006077152A2 (en) 2006-07-27
WO2006077152A3 true WO2006077152A3 (en) 2006-10-26

Family

ID=36601159

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/000560 Ceased WO2006077152A2 (en) 2005-01-21 2006-01-23 Hla fusion molecules and uses thereof

Country Status (3)

Country Link
EP (1) EP1919949A2 (en)
CA (1) CA2595462A1 (en)
WO (1) WO2006077152A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103382224A (en) * 2013-06-28 2013-11-06 英科隆生物技术（杭州）有限公司 Heterocross-linked products containing hetero-cross-linked antibodies in tetrameric form and applications thereof
US9943578B2 (en) 2012-05-08 2018-04-17 Western University Of Health Sciences Standardized ex vivo platforms for the antigen-specific expansion of CD4+ T cell populations

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999009064A1 (en) * 1997-08-19 1999-02-25 Mount Sinai School Of Medicine Of New York University ; Epitope-bearing major histocompatibility complex class ii element/immunoglobulin chimeric molecules
WO1999042597A1 (en) * 1998-02-19 1999-08-26 President And Fellows Of Harvard College Monovalent, multivalent, and multimeric mhc binding domain fusion proteins and conjugates, and uses therefor
WO2001091698A2 (en) * 2000-06-01 2001-12-06 Gavish Galilee Bio Appl Ltd Genetically-engineered mhc molecules
WO2003025000A2 (en) * 2001-09-17 2003-03-27 Nalan Utku Peptides capable of modulating immune response

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999009064A1 (en) * 1997-08-19 1999-02-25 Mount Sinai School Of Medicine Of New York University ; Epitope-bearing major histocompatibility complex class ii element/immunoglobulin chimeric molecules
WO1999042597A1 (en) * 1998-02-19 1999-08-26 President And Fellows Of Harvard College Monovalent, multivalent, and multimeric mhc binding domain fusion proteins and conjugates, and uses therefor
WO2001091698A2 (en) * 2000-06-01 2001-12-06 Gavish Galilee Bio Appl Ltd Genetically-engineered mhc molecules
WO2003025000A2 (en) * 2001-09-17 2003-03-27 Nalan Utku Peptides capable of modulating immune response

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NAG B ET AL: "Functionally active recombinant alpha and beta chain-peptide complexes of human major histocompatibility class II molecules", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,, US, vol. 271, no. 17, 26 April 1996 (1996-04-26), pages 10413 - 10418, XP002110049, ISSN: 0021-9258 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9943578B2 (en) 2012-05-08 2018-04-17 Western University Of Health Sciences Standardized ex vivo platforms for the antigen-specific expansion of CD4+ T cell populations
CN103382224A (en) * 2013-06-28 2013-11-06 英科隆生物技术（杭州）有限公司 Heterocross-linked products containing hetero-cross-linked antibodies in tetrameric form and applications thereof

Also Published As

Publication number Publication date
CA2595462A1 (en) 2006-07-27
EP1919949A2 (en) 2008-05-14
WO2006077152A2 (en) 2006-07-27

Similar Documents

Publication Publication Date Title
WO2001052791A3 (en) Complexes of peptide-binding fragments of heat shock proteins and their use as immunotherapeutic agents
WO2004010957A3 (en) Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
WO2006135434A3 (en) Semi-soft c-class immunostimulatory oligonucleotides
WO2007053189A3 (en) Compositions and methods for altering immune function
EP2388271A3 (en) Human Antibodies and Proteins
EP2182006A3 (en) Compositions and methods for the treatment of immune related diseases
EP1777234A3 (en) Methods of treatment of inflammatory diseases using specific binding agents of human angiopoietin - 2
WO2006076594A3 (en) Antibodies and fc fusion proteins with altered immunogenicity
ATE507204T1 (en) ISOINDOLIN COMPOUNDS AND THEIR USES
DE60206512D1 (en) RAPANYCIN29-enols
EP2298308A3 (en) Integrin-binding small molecules
ATE395082T1 (en) ANTIBODIES TO CANCER ANTIGEN TMEFF2 AND ITS APPLICATIONS
WO2004029072A3 (en) PrPsc -INTERACTING MOLECULES AND USES THEREOF
CY1112620T1 (en) COMPOSITIONS WHICH INCLUDE MYELINE BASIC PROTEIN PATIENTS AND THEIR MEDICAL USES
SI1622939T1 (en) Active variants of the il-18 binding protein and medical uses thereof
WO2004099388A3 (en) Cbl-b polypeptides, complexes and related methods
WO2006077152A3 (en) Hla fusion molecules and uses thereof
WO2007059341A3 (en) Pyrazolothiazole protein kinase modulators
WO2008051448A3 (en) Methods and compositions for efficient removal of protein a from binding molecule preparations
WO2003027251A3 (en) Novel molecules of the pyrin domain protein family and uses thereof
WO2001007479A3 (en) Fragments of cellular prion protein and methods useful in the diagnosis and treatment of prion diseases
HK1079984A1 (en) Glycinamide derivative for inhibiting hiv replication
WO2004083241A3 (en) Btc-interacting proteins and use thereof
EP1262491A3 (en) Non-anaphylactogenic IgE vaccines
WO2004073625A3 (en) Inhibitors of antigen presentation by mhc class ii molecules and methods of use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2595462

Country of ref document: CA

Ref document number: 2007551628

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006706364

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWP Wipo information: published in national office

Ref document number: 2006706364

Country of ref document: EP